Tekton’s Austin, TX, team screened the first participant globally for Boehringer Ingelheim’s Phase 3 study evaluating nerandomilast for systemic sclerosis.
Congratulations to Paul Pickrell, MD, and our entire Austin team on this milestone!
Austin Site Screens First Participant Globally for Boehringer Ingelheim Systemic Sclerosis Study
August 17, 2026
Posted in News
The Latest From Tekton
-
St. Louis Team Exceeds Enrollment Goal in Alzheimer’s Trial
Celebrating a job well done by Ernest Graypel, MD, MHA, Brandon Lenfest, Mejra Dzinic, and our St. Louis team! After joining an Alzheimer’s trial as a rescue site, the team … Read more
-
Tekton Adds Executive Leadership Across Key Therapeutic Areas and Patient Engagement
Tekton Research, a multi-specialty clinical research site organization, has hired three vice presidents to lead its neuroscience, cardiometabolic, and endocrinology research operations, and to advance its patient engagement strategy. All … Read more
-
Introducing the Tekton Psychiatry Team
Tekton has introduced the Tekton Psychiatry Team, bringing together physician-investigators and operational leaders to provide centralized expertise for mental and behavioral health studies across 17 Tekton sites. From protocol review and … Read more
-
Tekton Sites Achieve 300% of Combined Obesity Trial Enrollment Goal
Tekton Research’s San Antonio, TX, and Edmond, OK, teams achieved 300% of their combined initial enrollment goal for a recent Phase 2 obesity trial, randomizing 60 participants against a target … Read more
